BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Miels will formally assume the role on January 1, 2026
LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment
FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Air Liquide will provide care for people living with respiratory diseases such as chronic obstructive pulmonary disease (COPD) and sleep apnea
Subscribe To Our Newsletter & Stay Updated